The annual World-Leading Course in interventional cardiovascular medicine is the official meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI).  Thousands of participants will once again be gathering to share their knowledge, skills and experience on 20-23 May 2025, at the Palais des Congrès in...

Mirvat Alasnag provides her take on the ECMO-CS trial, which was presented during AHA 2022 in Chicago, and simultaneously published in Circulation. 

Ali Nazmi Calik provides his take on UNIVERSAL randomized clinical trial, which questioned whether routine ultrasonography guidance for CFA access for cardiac procedures reduces bleeding or vascular complications. This trial was presented by Sanjit S. Jolly during TCT 2022.

 
Forty years ago, Andreas Grüntzig performed the world’s first coronary angioplasty (PCI)—fundamentally changing the management of coronary artery disease. Bernhard Meier, who worked with A. Grüntzig and actually identified the patient for the procedure, talks to The Daily Wire about this first procedure and about his...

Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.

Luigi Biasco reports the best of Dj Lakkireddy (Overland Park, USA)'s presentation of the AMULET IDE trial at the Monday, August 30 Hot Line session of the ESC Congress 2021.

Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.

Nicola Ryan provides her take on the ALIGN AR trial which was presented by Vinod H. Thourani at TCT Congress 2023. The Align AR trial is a prospective single-arm investigation device exemption study assessing the safety and efficacy of the Trilogy transcatheter heart valve system in patients with...

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

View a number of questions of interest to the interventional cardiovascular community, as well as the real-world applicability of COVID-19 vaccine trials.

PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB trials were presented at TCT Connect 2020. Hector Garcia-Garcia provides a summary of the key messages.

Majority of ischemic heart disease patients present with NSTEACS . Management of NSTEACS starts with correct diagnosis, appropriate timely initiation of the right pharmacotherapy, provision of coronary angiography/intervention procedures and secondary preventative care. 5 years on from the last ESC NSTEACS guidelines, what does the new...

In collaboration with EuroIntervention Journal

The authors decided to create a survey tailored for ICTs in order to assess the changes in their training. Capturing the essence of the responses may help to identify the most appropriate strategies to provide the highest standards and skills achievements in COVID-19...

Alex Sticchi provides his take on PRECISE, which was presented during AHA 2022 in Chicago.

Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)